OSR Holdings discloses Pexa-Vec license talks and potential SillaJen controlling stake

OSR Holdings, Inc.

Vaximm in active negotiations with SillaJen to license Pexa-Vec, a Phase 2 oncolytic immunotherapy for renal cell carcinoma.
OSR Holdings held preliminary verbal talks to acquire ~16% controlling stake in SillaJen (KOSDAQ:215600).
No binding term sheet, letter of intent, or definitive agreement exists for either matter.
Disclosed to comply with Regulation FD after inadvertent reference during March 13 analyst call.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.